Position in INCY
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,113,370
+$358,691 QoQ
Shares Held
18,643
0.0% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#322
of 849 holders
Holding Since
Jun 2023
12 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INCY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026OAK ASSOCIATES LTD /OH/ holds $19,769,546 across 6 Biotechnology names. INCY ranks #5 (10.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
10,560 | $6,584,582 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
17,722 | $4,270,470 | |
| 3 | EXEL |
Exelixis, Inc.
|
73,764 | $4,013,499 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,677 | $2,323,206 | |
| 5 | INCY |
Incyte Corp
This page
|
18,643 | $2,113,370 | |
| 6 | INVA |
Innoviva, Inc.
|
20,450 | $464,419 |
All Filings in INCY
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,113,370 | 18,643 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,754,679 | 18,643 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,841,369 | 18,643 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $1,613,255 | 19,022 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $1,295,398 | 19,022 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $1,151,782 | 19,022 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $1,313,849 | 19,022 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $1,290,404 | 19,522 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $1,183,423 | 19,522 | Shares | Sole | 2024-08-08 | |
| 2024-03-31 | $1,112,168 | 19,522 | Shares | Sole | 2024-05-10 | |
| 2023-09-30 | $1,483,822 | 25,685 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $1,721,274 | 27,651 | Shares | Sole | 2023-08-11 | |
| No filing history on record for this holder in this stock. | ||||||